107 related articles for article (PubMed ID: 9678640)
1. Methamphetamine-induced Fos expression in the substantia nigra pars reticulata in rats with a unilateral 6-OHDA lesion of the nigrostriatal fibers.
Ishida Y; Todaka K; Kuwahara I; Nakane H; Ishizuka Y; Nishimori T; Mitsuyama Y
Neurosci Res; 1998 Apr; 30(4):355-60. PubMed ID: 9678640
[TBL] [Abstract][Full Text] [Related]
2. Methamphetamine induces fos expression in the striatum and the substantia nigra pars reticulata in a rat model of Parkinson's disease.
Ishida Y; Todaka K; Kuwahara I; Ishizuka Y; Hashiguchi H; Nishimori T; Mitsuyama Y
Brain Res; 1998 Oct; 809(1):107-14. PubMed ID: 9795171
[TBL] [Abstract][Full Text] [Related]
3. Dopaminergic transplants suppress L-DOPA-induced Fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease.
Ishida Y; Kuwahara I; Todaka K; Hashiguchi H; Nishimori T; Mitsuyama Y
Brain Res; 1996 Jul; 727(1-2):205-11. PubMed ID: 8842399
[TBL] [Abstract][Full Text] [Related]
4. Dizocilpine maleate, MK-801, but not 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline, NBQX, prevents transneuronal degeneration of nigral neurons after neurotoxic striatal-pallidal lesion.
DeGiorgio LA; DeGiorgio N; Volpe BT
Neuroscience; 1999 Apr; 90(1):79-85. PubMed ID: 10188935
[TBL] [Abstract][Full Text] [Related]
5. Substantia nigra glutamate antagonists produce contralateral turning and basal ganglia Fos expression: interactions with D1 and D2 dopamine receptor agonists.
McPherson RJ; Marshall JF
Synapse; 2000 Jun; 36(3):194-204. PubMed ID: 10819899
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical evidence for a neurotensin striatonigral pathway in the rat brain.
Castel MN; Morino P; Frey P; Terenius L; Hökfelt T
Neuroscience; 1993 Aug; 55(3):833-47. PubMed ID: 8105419
[TBL] [Abstract][Full Text] [Related]
7. The corticostriatal system mediates the "paradoxical" contraversive rotation but not the striatal hyperexpression of Fos induced by amphetamine early after 6-hydroxydopamine lesion of the nigrostriatal pathway.
Lopez-Martin E; Rozas G; Rodriguez J; Guerra MJ; Labandeira-Garcia JL
Exp Brain Res; 1998 May; 120(2):153-63. PubMed ID: 9629957
[TBL] [Abstract][Full Text] [Related]
8. Functional neuroanatomy of the nigrostriatal and striatonigral pathways as studied with dual probe microdialysis in the awake rat--II. Evidence for striatal N-methyl-D-aspartate receptor regulation of striatonigral GABAergic transmission and motor function.
Morari M; O'Connor WT; Ungerstedt U; Bianchi C; Fuxe K
Neuroscience; 1996 May; 72(1):89-97. PubMed ID: 8730708
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of Fos and Zif268 in the nigrostriatal system after methamphetamine administration in a rat model of Parkinson's disease.
Ishida Y; Kawai K; Magata Y; Ebihara K; Takeda R; Abe H; Yoshimoto M; Hashiguchi H; Odagiri K; Matsuo H; Nishimori T
Synapse; 2008 Dec; 62(12):920-6. PubMed ID: 18792992
[TBL] [Abstract][Full Text] [Related]
10. Modulation of dopamine D1-mediated turning behavior and striatal c-fos expression by the substantia nigra.
Fenu S; Carta A; Morelli M
Synapse; 1995 Apr; 19(4):233-40. PubMed ID: 7792718
[TBL] [Abstract][Full Text] [Related]
11. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease.
Armentero MT; Fancellu R; Nappi G; Bramanti P; Blandini F
Neurobiol Dis; 2006 Apr; 22(1):1-9. PubMed ID: 16289868
[TBL] [Abstract][Full Text] [Related]
12. NMDA receptors mediate an early up-regulation of brain-derived neurotrophic factor expression in substantia nigra in a rat model of presymptomatic Parkinson's disease.
Bustos G; Abarca J; Bustos V; Riquelme E; Noriega V; Moya C; Campusano J
J Neurosci Res; 2009 Aug; 87(10):2308-18. PubMed ID: 19326433
[TBL] [Abstract][Full Text] [Related]
13. N-methyl-D-aspartate receptor blockade attenuates D1 dopamine receptor modulation of neuronal activity in rat substantia nigra.
Huang KX; Bergstrom DA; Ruskin DN; Walters JR
Synapse; 1998 Sep; 30(1):18-29. PubMed ID: 9704877
[TBL] [Abstract][Full Text] [Related]
14. N-methyl-D-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D1 and D2 dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion.
Engber TM; Anderson JJ; Boldry RC; Kuo S; Chase TN
Neuroscience; 1993 Jun; 54(4):1051-61. PubMed ID: 8101981
[TBL] [Abstract][Full Text] [Related]
15. Effect of MK 801 on priming of D1-dependent contralateral turning and its relationship to c-fos expression in the rat caudate-putamen.
Morelli M; Fenu S; Carta A; Di Chiara G
Behav Brain Res; 1996 Sep; 79(1-2):93-100. PubMed ID: 8883820
[TBL] [Abstract][Full Text] [Related]
16. Reformation of the nigrostriatal pathway by fetal dopaminergic micrografts into the substantia nigra is critically dependent on the age of the host.
Bentlage C; Nikkhah G; Cunningham MG; Björklund A
Exp Neurol; 1999 Sep; 159(1):177-90. PubMed ID: 10486186
[TBL] [Abstract][Full Text] [Related]
17. Role of a 35 kDa fos-related antigen (FRA) in the long-term induction of striatal dynorphin expression in the 6-hydroxydopamine lesioned rat.
Bronstein DM; Ye H; Pennypacker KR; Hudson PM; Hong JS
Brain Res Mol Brain Res; 1994 May; 23(3):191-203. PubMed ID: 7914658
[TBL] [Abstract][Full Text] [Related]
18. Intranigral injections of glutamate antagonists modulate dopamine D1-mediated turning behavior and striatal c-fos expression.
Fenu S; Carta A; Morelli M
J Neural Transm Suppl; 1995; 45():75-81. PubMed ID: 8748612
[TBL] [Abstract][Full Text] [Related]
19. Deafferentiation-induced c-fos gene expression in subthalamic nucleus and substantia nigra reticulata is reduced by non-NMDA receptor antagonist.
Saji M; Kimura M; Ishida G; Ohno K
Brain Res; 1995 Dec; 703(1-2):165-74. PubMed ID: 8719629
[TBL] [Abstract][Full Text] [Related]
20. Blockade of NMDA receptors by MK-801 reverses the changes in striatal glutamate immunolabeling in 6-OHDA-lesioned rats.
Robinson S; Krentz L; Moore C; Meshul CK
Synapse; 2001 Oct; 42(1):54-61. PubMed ID: 11668591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
